We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER’s Office of New Drugs Touts Research Outcomes for Fiscal 2022-2023
CDER’s Office of New Drugs Touts Research Outcomes for Fiscal 2022-2023
CDER’s Office of New Drugs (OND) touted accomplishments by the research program it launched in 2019 to address knowledge gaps identified during regulatory reviews.
